Please Wait.....
Report
Brazil Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-05-01 I 76 Pages I Allied Market Research
The radiopharmaceuticals market in Brazil is anticipated to experience considerable development over the forecast period. The market is witnessing a surge for radiopharmaceuticals due to factors such as increased prevalence of cancer, growing investments in the healthcare field, and increased access to healthcare in Brazil. The Brazil radiopharmaceuticals market is also attracting focus of foreign players, causing a high competition in the market.
The federal government initiatives to improve public access to healthcare, increase medical care investing, and concentrate on healthcare digitization are raising the uptake of radiopharmaceuticals in the Brazilian market. Moreover, the high number of people suffering from chronic diseases like cancer and the growing need for customized medication are anticipated to drive the market. Additionally, technological improvements and the introduction of new radiopharmaceuticals such as technetium-99m are driving the growth of the market.
Opportunities for the Brazil radiopharmaceuticals market include the advancement in treatment alternatives for chronic diseases, such as cancer cell immunotherapy and targeted radiotherapy. Furthermore, technological improvements in imaging have made it much easier to identify cancer cells and lump sites, resulting in more target-specific therapy. Additionally, the introduction of new radiopharmaceuticals with minimal side effects and improved efficacy has made it possible for market players to expand their product portfolio and venture into untapped sectors in the market. Furthermore, partnerships between universities, government bodies, and clinical research institutes can result in the advancement of innovative products and enhance market penetration.
Despite the driving factors, the market is limited by the high cost of radiopharmaceuticals, absence of knowledge and skilled personnel for production as well as handling of radioisotopes. Furthermore, there are stringent guidelines in radiopharmaceutical production as well as handling of radiopharmaceuticals in Brazil. Rising investments in the medical care industry and boosting public access to healthcare are expected to result in tremendous opportunities for the Brazil radiopharmaceuticals market in the future. Additionally, the introduction of more advanced radiopharmaceuticals will provide significant opportunities for the market players. For example, the introduction of fluorine-18 and gallium-68 radioisotopes over the last few years will certainly create high investment opportunities for the Brazil radiopharmaceuticals market.
The need for radiopharmaceuticals in the Brazilian market is anticipated to keep propelling throughout the forecast duration. This is attributed to the expanding financial investments in the medical care industry, federal government initiatives, and increasing public awareness pertaining to health care in Brazil. Additionally, the new and more advanced radioisotopes such as technetium-99m, iodine-I, and also gallium-68 are expected to be increasingly utilized in the Brazilian market. Additionally, a rise in the number of cancer patients and the emerging trend of tailored medication will contribute to the growth of the Brazil radiopharmaceuticals market.
The Brazil radiopharmaceuticals market is segmented based upon the radioisotope, application, and end user. Based on radioisotope, the market is divided into technetium 99m, fluorine 18, iodine I, gallium 68, and others. Based on application, the market is divided into cancer, cardiology, and others. Based on type, the market is divided into diagnostic and therapeutic. Based on end user, the market is divided into hospitals & clinics, medical imaging centers, and others.
The Brazil radiopharmaceuticals market is witnessing growth with high investments in the medical care field as well as growing public awareness of medical care in the nation. The increasing number of cancer patients as well as the growing demand for individualized medicine will certainly create a raised need for radiopharmaceuticals in Brazil. Additionally, new as well as advanced radiopharmaceuticals are expected to be progressively made use of in the Brazilian market. The high number of health centers as well as facilities with sophisticated equipment will promote the growth of the Brazil radiopharmaceuticals market.
The high influx of cancer patients is expected to cause significant expansion in the Brazil radiopharmaceuticals market over the course of the forecast period. In addition, financial investments from the government in healthcare framework and the introduction of brand-new radiopharmaceuticals with improved efficiency are expected to fuel the development of the market in the country. The northern region of Brazil is expected to be the fastest-growing market throughout the forecast period, attributable to the desirable reimbursement policies and the number of medical care centers in the region.
The Porter's five forces analysis of the Brazil radiopharmaceuticals market is a helpful tool to assess the degree of competition as well as attractiveness of the market. The negotiating power of customers in the Brazil radiopharmaceuticals market is high, as there is low switching expense as well as high accessibility to the purchasers in the market. Additionally, the bargaining power of distributors in the Brazil radiopharmaceuticals market is high, owing to minimal capital expense as well as great understanding of the market to the vendors. The competitive rivalry in the Brazil radiopharmaceuticals market is high because of the existence of various players offering competitive products.
Key Benefits for Stakeholders
Enabled informed decision-making process and market analysis based on current market situation and estimated future trends.
Analysis of the key strategies adopted by major market players in Brazil radiopharmaceuticals market.
Assess and rank the top factors that are expected to affect the growth of Brazil radiopharmaceuticals market.
Top player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the Brazil radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis
Key Market Segments
By Type
- Diagnostic
- Therapeutic
By End User
- Hospitals and clinics
- Medical Imaging centers
- Others
By Radioisotope
- Fluorine 18
- Iodine I
- Gallium 68
- Others
- Technetium 99m
By Application
- Cancer
- Cardiology
- Others
- Key Market Players
- BRABCOOK Pharmaceuticals
- Cristalia
- AROMAR
- National Radiopharmaceuticals
- Buclizine
- Anadigm
- ALLERGAN Groups
- Gama Medica
- FcSm
- Zepp Online Laboratories
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter's Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: BRAZIL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market Size and Forecast, By Radioisotope
4.2. Technetium 99m
4.3. Fluorine 18
4.4. Iodine I
4.5. Gallium 68
4.6. Others
CHAPTER 5: BRAZIL RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Cancer
5.3. Cardiology
5.4. Others
CHAPTER 6: BRAZIL RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market Size and Forecast, By Type
6.2. Diagnostic
6.3. Therapeutic
CHAPTER 7: BRAZIL RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market Size and Forecast, By End User
7.2. Hospitals and clinics
7.3. Medical Imaging centers
7.4. Others
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. BRABCOOK Pharmaceuticals
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Cristalia
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. AROMAR
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. National Radiopharmaceuticals
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Buclizine
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Anadigm
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. ALLERGAN Groups
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Gama Medica
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. FcSm
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Zepp Online Laboratories
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. BRAZIL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. BRAZIL RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. BRAZIL RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. BRAZIL RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 05. BRABCOOK PHARMACEUTICALS: KEY EXECUTIVES
TABLE 06. BRABCOOK PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 07. BRABCOOK PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 08. BRABCOOK PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 09. BRABCOOK PHARMACEUTICALS: KEY STRATERGIES
TABLE 10. CRISTALIA: KEY EXECUTIVES
TABLE 11. CRISTALIA: COMPANY SNAPSHOT
TABLE 12. CRISTALIA: OPERATING SEGMENTS
TABLE 13. CRISTALIA: PRODUCT PORTFOLIO
TABLE 14. CRISTALIA: KEY STRATERGIES
TABLE 15. AROMAR: KEY EXECUTIVES
TABLE 16. AROMAR: COMPANY SNAPSHOT
TABLE 17. AROMAR: OPERATING SEGMENTS
TABLE 18. AROMAR: PRODUCT PORTFOLIO
TABLE 19. AROMAR: KEY STRATERGIES
TABLE 20. NATIONAL RADIOPHARMACEUTICALS: KEY EXECUTIVES
TABLE 21. NATIONAL RADIOPHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 22. NATIONAL RADIOPHARMACEUTICALS: OPERATING SEGMENTS
TABLE 23. NATIONAL RADIOPHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 24. NATIONAL RADIOPHARMACEUTICALS: KEY STRATERGIES
TABLE 25. BUCLIZINE: KEY EXECUTIVES
TABLE 26. BUCLIZINE: COMPANY SNAPSHOT
TABLE 27. BUCLIZINE: OPERATING SEGMENTS
TABLE 28. BUCLIZINE: PRODUCT PORTFOLIO
TABLE 29. BUCLIZINE: KEY STRATERGIES
TABLE 30. ANADIGM: KEY EXECUTIVES
TABLE 31. ANADIGM: COMPANY SNAPSHOT
TABLE 32. ANADIGM: OPERATING SEGMENTS
TABLE 33. ANADIGM: PRODUCT PORTFOLIO
TABLE 34. ANADIGM: KEY STRATERGIES
TABLE 35. ALLERGAN GROUPS: KEY EXECUTIVES
TABLE 36. ALLERGAN GROUPS: COMPANY SNAPSHOT
TABLE 37. ALLERGAN GROUPS: OPERATING SEGMENTS
TABLE 38. ALLERGAN GROUPS: PRODUCT PORTFOLIO
TABLE 39. ALLERGAN GROUPS: KEY STRATERGIES
TABLE 40. GAMA MEDICA: KEY EXECUTIVES
TABLE 41. GAMA MEDICA: COMPANY SNAPSHOT
TABLE 42. GAMA MEDICA: OPERATING SEGMENTS
TABLE 43. GAMA MEDICA: PRODUCT PORTFOLIO
TABLE 44. GAMA MEDICA: KEY STRATERGIES
TABLE 45. FCSM: KEY EXECUTIVES
TABLE 46. FCSM: COMPANY SNAPSHOT
TABLE 47. FCSM: OPERATING SEGMENTS
TABLE 48. FCSM: PRODUCT PORTFOLIO
TABLE 49. FCSM: KEY STRATERGIES
TABLE 50. ZEPP ONLINE LABORATORIES: KEY EXECUTIVES
TABLE 51. ZEPP ONLINE LABORATORIES: COMPANY SNAPSHOT
TABLE 52. ZEPP ONLINE LABORATORIES: OPERATING SEGMENTS
TABLE 53. ZEPP ONLINE LABORATORIES: PRODUCT PORTFOLIO
TABLE 54. ZEPP ONLINE LABORATORIES: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. BRAZIL RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF BRAZIL RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN BRAZIL RADIOPHARMACEUTICALS MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: BRAZIL RADIOPHARMACEUTICALS MARKET
FIGURE 10. BRAZIL RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
FIGURE 11. BRAZIL RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. BRAZIL RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
FIGURE 13. BRAZIL RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 18. COMPETITIVE DASHBOARD
FIGURE 19. COMPETITIVE HEATMAP: BRAZIL RADIOPHARMACEUTICALS MARKET
FIGURE 20. TOP PLAYER POSITIONING, 2022
FIGURE 21. BRABCOOK PHARMACEUTICALS: NET SALES, 2020-2022*($MILLION)
FIGURE 22. BRABCOOK PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 23. BRABCOOK PHARMACEUTICALS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 24. CRISTALIA: NET SALES, 2020-2022*($MILLION)
FIGURE 25. CRISTALIA: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 26. CRISTALIA: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 27. AROMAR: NET SALES, 2020-2022*($MILLION)
FIGURE 28. AROMAR: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 29. AROMAR: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 30. NATIONAL RADIOPHARMACEUTICALS: NET SALES, 2020-2022*($MILLION)
FIGURE 31. NATIONAL RADIOPHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 32. NATIONAL RADIOPHARMACEUTICALS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 33. BUCLIZINE: NET SALES, 2020-2022*($MILLION)
FIGURE 34. BUCLIZINE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 35. BUCLIZINE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 36. ANADIGM: NET SALES, 2020-2022*($MILLION)
FIGURE 37. ANADIGM: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 38. ANADIGM: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 39. ALLERGAN GROUPS: NET SALES, 2020-2022*($MILLION)
FIGURE 40. ALLERGAN GROUPS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 41. ALLERGAN GROUPS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 42. GAMA MEDICA: NET SALES, 2020-2022*($MILLION)
FIGURE 43. GAMA MEDICA: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 44. GAMA MEDICA: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 45. FCSM: NET SALES, 2020-2022*($MILLION)
FIGURE 46. FCSM: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 47. FCSM: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 48. ZEPP ONLINE LABORATORIES: NET SALES, 2020-2022*($MILLION)
FIGURE 49. ZEPP ONLINE LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 50. ZEPP ONLINE LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security